Drug reference
dostarlimab
humanized IgG4 monoclonal antibody, PD-1 inhibitor, immune checkpoint inhibitor · anticancer, immunomodulator
humanized IgG4 monoclonal antibody, PD-1 inhibitor, immune checkpoint inhibitoranticancer, immunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Dostarlimab is a humanized IgG4 monoclonal PD-1–blocking antibody.
Indications
mismatch repair–deficient chemotherapy-resistant endometrial cancer
Related guidelines
Ask House about dostarlimab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team